However, a number of studies have shown modest responses to ipilimumab in other tumor types such as metastatic RCC and NSCLC, and it continues to be studied in clinical trials as combination therapy with PD-1/PD-L1 (discussed below) (160, 167). Here, CD274 is linked to neoplasm.